3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
36
Gastrointestinal
11
Tumor-Agnostic
10
Other hematologic neoplasm
8
Head & Neck
6
Endocrine
5
Plasma cell
4
Lymphoid
4
CNS
4
Thoracic
3
Breast
3
Sarcoma
2
Other solid neoplasm
2
Myeloid
2
Gynecologic
2
Genitourinary
2
Classical hematology
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Genomic Instability
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
510
Cisplatin
410
Pemetrexed
400
Radiotherapy
285
Docetaxel
244
Paclitaxel
228
pembrolizumab
226
Gemcitabine
198
Drug Therapy
191
Bevacizumab
190
Erlotinib Hydrochloride
189
Radiosurgery
177
Nivolumab
168
durvalumab
155
Etoposide
155
osimertinib
126
atezolizumab
109
Gefitinib
96
Blood Specimen Collection
93
Magnetic Resonance Spectroscopy
91
Vinorelbine
90
anlotinib
89
Surgical Procedures, Operative
85
Ipilimumab
62
Immunotherapy
62
Surveys and Questionnaires
60
sintilimab
59
Specimen Handling
59
tislelizumab
58
Irinotecan
57
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
OTHER
×
Vemurafenib
×
Thoracic
×
Clear all
NCT02314481
2026-05-04
DARWINII
University College, London
Phase 2
Completed
50 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled